Amgen released positive Phase III data from a small trial of its potentially first-in-class RANK ligand inhibitor denosumab at the San Antonio Breast Cancer Symposium Dec. 14. Amgen described data from a 252-patient trial observing denosumab versus placebo for treatment-induced bone loss in HR+ nonmetastatic breast cancer patients receiving aromatase inhibitor therapy. Patients were randomized to receive either twice yearly subcutaneous 60 mg injections of denosumab or placebo. The primary endpoint...